NuCana plc (NCNA) Stock

About NuCana plc

NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.

NuCana plc is headquartered in GB.

NuCana plc (NCNA) stock trades at $1.35 with a market capitalization of $8.20M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.14, reflecting a net loss over the last twelve months, price-to-book of 0.16, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.21 and $13.00, and currently trades 89.6% below its 52-week high.

On profitability, NuCana plc generates a return on equity (ROE) of -153.80% (negative, reflecting a net loss), return on capital employed of -93.95%.

Official website: www.nucana.com

NuCana plc by the numbers, 2016–2025

Between 2016 and 2025 NuCana plc reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-29.0M.

On a trailing twelve-month basis to Mar '26, revenue is $0 and net profit $-30.0M.

Borrowings stand at $1.0M, cash on hand is $21.5M, cash from operations was $-7.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged -153.7% over five years, and was -120.8% in the most recent year.

The share price itself has compounded at -84.2% a year over five years, -93.3% over three, -86.5% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

NuCana plc (NCNA) — frequently asked questions